The interest in USP32 as a therapeutic target was generated following the study of Zhang and colleagues, which identified USP32 as the prognostic gene with copy number alterations in estrogen receptor-positive human breast tumors [34]. This evidence concerns the gene USP32 and breast neoplasm.